Pfizer (PFE) to Release Earnings on Tuesday

Pfizer (NYSE:PFE - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 4th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $17.28 billion for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. The company's revenue for the quarter was up 31.2% compared to the same quarter last year. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Stock Down 0.3 %

NYSE PFE traded down $0.08 during trading hours on Tuesday, hitting $26.79. 40,577,144 shares of the company were exchanged, compared to its average volume of 36,131,742. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $151.79 billion, a price-to-earnings ratio of 36.20, a PEG ratio of 0.64 and a beta of 0.64. The company has a 50 day moving average of $26.15 and a two-hundred day moving average of $27.92. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.42%. Pfizer's dividend payout ratio (DPR) is 227.03%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PFE shares. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a "market perform" rating and a $32.00 target price for the company. Bank of America reiterated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Finally, Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.